Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:


Expert Insights on the Use of PCSK9 Inhibitors in Interventional Cardiology

Access Activity

Overview / Abstract:

This roundtable discussion includes a panel of three faculty experts, who review clinical evidence related to the use of PCSK9 inhibitors in managing hyperlipidemia. Utilizing supporting clinical data and real-world experience, the faculty discuss how gaps in patient care can be improved via increased recognition of high-risk patients, application of clinical trial data, and selection of therapies in complex patients.

Treatment decisions for hyperlipidemia are increasingly challenging due to changing guidelines and a new class of therapies, the PCSK9 inhibitors. Further, clinicians must have competence in identifying high-risk patients who may require intensification or switching to a new therapy. Data from the cardiovascular outcomes trials with the PCSK9 inhibitors can assist in the identification of eligible at-risk patients. Interventional cardiologists require up-to-date knowledge of these new therapies and data since they are likely to encounter high-risk patients with hyperlipidemia.

Upon completion of this activity, participants will be able to:
• Outline considerations in the selection of LDL cholesterol targets across diverse patient populations
• Compare and contrast study designs, endpoints, and results of cardiovascular outcomes clinical trials of the PCSK9 inhibitors
• Identify high-risk patients who may be candidates for a PCSK9 inhibitor
• Formulate individualized treatment strategies for complex patients based on available evidence
• Discuss strategies to overcome barriers and ensure appropriate use of PCSK9 inhibitors in interventional cardiology settings


Aug 28, 2019


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME, Surgical Technology CE


Online, Webinar / Webcast / Video

Credits / Hours




Is This Activity Certified for "Live" Credit?


Presenters / Authors / Faculty

Rajesh Dave, MD, FACC, FSCAI (Moderator)
Chief Medical Executive
Holy Spirit Cardiovascular Institute
Chairman, Department of Cardiology
Director, Cardiac Catheterization Laboratories
The Ortenzio Heart Center at Holy Spirit Hospital
Camp Hill, Pennsylvania

Nihar Desai, MD, MPH
Assistant Professor of Medicine
Yale School of Medicine
New Haven, Connecticut

Robert Giugliano, MD, SM
Associate Professor of Medicine
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Activity Specialities / Related Topics

Anticoagulation / Thrombosis, Cardiology / Cardiovascular, Dyslipidemia / Cholesterol, Education / Teaching, Family Medicine, Hypertension / Blood Pressure, Internal Medicine, Podiatry, Primary Care

Sponsors / Supporters / Grant Providers

Sponsored by the Academy for Continued Healthcare Learning (ACHL) and the Interventional Academy.

Supported by an educational grant from Amgen Inc.

Keywords / Search Terms

ACHL CME, CE, Continuing Medical Education, CME/CE, Online Learning, Webcasts, Newsletter, Case Study, Live Meetings, Slidekit, Monograph, Journal, Cardiology, interventional cardiology, PCSK9, hyperlipidemia, Interventional Academy, C3 2018, Amgen, FOURIER, ODYSSEY, Dave, Giugliano, Desai, LDL-C, HDL-C, blood cholesterol, evolocumab, alirocumab, Raj Dave, Dave, Robert Giugliano, Giugliano, Nihar Desai, Desai Free CE CME Live CE CME

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.